
Plus Therapeutics (NASDAQ:PSTV) has concluded patient enrolment in the first cohort of the ReSPECT-LM Phase 1/2a dose escalation clinical trial of Rhenium-186 NanoLiposome (186RNL) for the treatment of leptomeningeal metastases (LM).
The company is planning to provide enrolment and complete clinical updates in the third quarter of 2022.